poisar

Stocks · News reference

IQVIA And Medera Announce Strategic Collaboration To Accelerate Cardiac Gene Therapy Development And Human-Based Drug Discovery Platforms

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IQV
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    AI in Clinical Trials Market Set for Transformative Growth Through 2040, Unlocking Opportunities Across Trial Phases, Therapeutic Areas, End Users and Key Global Regions

    The global AI in clinical trials market is projected to expand from USD 2.09 billion in 2026 to USD 18.62 billion by 2040, growing at a 17.0% CAGR. AI applications including patient recruitment, predictive analytics, digital twins, and automation are addressing key challenges in drug development timelines and trial efficiency. Oncology represents the largest therapeutic area, while Asia-Pacific shows significant growth potential. Key players include IQVIA, Medidata, Dassault Systemes, and emerging AI companies like Deep 6 AI and AiCure.

    IQVDASTYORCLORCLPDTEM
  2. Researchandmarkets.Com

    Europe Clinical Data Analytics Market Outlook 2026-2033 | AI, Cloud Deployment and Data-Driven Healthcare Adoption Accelerate Across the Region

    Europe's clinical data analytics market is projected to reach USD 105.6 billion by 2031, growing at a 27% CAGR through 2033. Growth is driven by healthcare digitalization, AI adoption, cloud deployment, and regulatory initiatives like the European Health Data Space. Software and cloud-based solutions lead the market, with healthcare providers and payers increasingly investing in analytics for improved patient outcomes and operational efficiency.

    UNHORCLORCLPDIQVDASTY
  3. SEC EDGAR

    8-K filing — IQVIA HOLDINGS INC. (IQV)

    Filed: 2026-09-23 AccNo: 0001193125-26-399616 Size: 893 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits

    IQV
  4. Researchandmarkets.Com

    Rare Disease Contract Research Organization (CRO) Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook

    The global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.

    TMOIQVLHICLRCRL